{"id":"thienopyridine-open-label","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombotic thrombocytopenic purpura (TTP)"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Gastrointestinal bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Thienopyridines are antiplatelet agents that irreversibly bind to the P2Y12 receptor, preventing adenosine diphosphate (ADP)-induced platelet activation and aggregation. This mechanism reduces thrombotic events by inhibiting platelet clumping and clot formation. They are commonly used to prevent stent thrombosis and reduce cardiovascular events in patients with acute coronary syndromes or undergoing percutaneous coronary intervention.","oneSentence":"Thienopyridines inhibit platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:27.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Prevention of stent thrombosis following percutaneous coronary intervention"},{"name":"Secondary prevention of cardiovascular events"}]},"trialDetails":[{"nctId":"NCT07454707","phase":"PHASE3","title":"Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Stroke, Ischemic","enrollment":1204},{"nctId":"NCT07275749","phase":"PHASE3","title":"Acetyl-leucine in Post-stroke Ataxia","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2025-12-01","conditions":"Ischemic Stroke","enrollment":200},{"nctId":"NCT07265466","phase":"PHASE1","title":"to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban","status":"RECRUITING","sponsor":"Onconic Therapeutics Inc.","startDate":"2025-11-17","conditions":"Drug Drug Interaction (DDI)","enrollment":96},{"nctId":"NCT05752916","phase":"PHASE4","title":"Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-06-02","conditions":"Acute Ischemic Stroke","enrollment":570},{"nctId":"NCT06857045","phase":"NA","title":"Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent Implantation","status":"WITHDRAWN","sponsor":"Sino Medical Sciences Technology Inc.","startDate":"2024-07-09","conditions":"Intracranial Arteriosclerosis, Intracranial Artery Stenosis, Drug-Eluting Stents","enrollment":""},{"nctId":"NCT06714526","phase":"NA","title":"Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-10-07","conditions":"Intracranial Atherosclerosis","enrollment":100},{"nctId":"NCT03378934","phase":"PHASE4","title":"Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2018-09-26","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention","enrollment":64},{"nctId":"NCT07180472","phase":"PHASE4","title":"Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Chengdu Medical College","startDate":"2025-09-20","conditions":"Cerebral Small Vessel Disease","enrollment":632},{"nctId":"NCT06591338","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-09-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06360120","phase":"PHASE3","title":"Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-04-10","conditions":"Ischemic Stroke","enrollment":600},{"nctId":"NCT07095790","phase":"PHASE4","title":"Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-08-30","conditions":"Mild Stroke","enrollment":580},{"nctId":"NCT03430661","phase":"PHASE1","title":"A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2018-01-24","conditions":"Healthy","enrollment":77},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT03496506","phase":"PHASE1","title":"A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2018-03-05","conditions":"Healthy Subjects","enrollment":22},{"nctId":"NCT03298906","phase":"PHASE1","title":"A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-09-26","conditions":"Healthy","enrollment":16},{"nctId":"NCT05353140","phase":"NA","title":"LAAO Versus NOAC in Patients with AF and PCI","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2022-09-01","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":1386},{"nctId":"NCT02398656","phase":"PHASE3","title":"A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2015-04-01","conditions":"Stroke, Acute","enrollment":1274},{"nctId":"NCT06591299","phase":"PHASE3","title":"Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-04-15","conditions":"Ischemic Stroke","enrollment":870},{"nctId":"NCT06591351","phase":"PHASE3","title":"Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-05-01","conditions":"Ischemic Stroke","enrollment":870},{"nctId":"NCT06591312","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-05-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT05141305","phase":"PHASE3","title":"Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-01-19","conditions":"Ischemic Stroke, Acute","enrollment":516},{"nctId":"NCT04305587","phase":"PHASE1","title":"Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-03-16","conditions":"Diabetes Mellitus Type 2","enrollment":66},{"nctId":"NCT05209412","phase":"NA","title":"Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-02-01","conditions":"De Novo Stenosis, Coronary Artery Disease, Percutaneous Coronary Intervention","enrollment":370},{"nctId":"NCT06164834","phase":"PHASE1","title":"Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2023-12-05","conditions":"Healthy","enrollment":48},{"nctId":"NCT06102720","phase":"PHASE4","title":"Efficacy of Colchicine in Preventing Recurrent Stroke in the Patients With Acute Atherothrombotic Ischemic Stroke During Hospitalization","status":"UNKNOWN","sponsor":"Mikhail Zykov","startDate":"2023-01-12","conditions":"Ischemic Stroke","enrollment":200},{"nctId":"NCT05162053","phase":"PHASE1","title":"PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers","status":"COMPLETED","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2021-12-09","conditions":"Acute Coronary Syndrome","enrollment":128},{"nctId":"NCT06088433","phase":"PHASE4","title":"Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease","status":"UNKNOWN","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2023-11-15","conditions":"Coronary Heart Disease","enrollment":292},{"nctId":"NCT06021990","phase":"PHASE3","title":"Clopidogrel for the Prevention of Exacerbations in Severe COPD","status":"UNKNOWN","sponsor":"Lady Reading Hospital, Pakistan","startDate":"2023-10-01","conditions":"COPD, COPD Exacerbation Acute","enrollment":162},{"nctId":"NCT05960721","phase":"NA","title":"Low-dose NOAC Versus GDMT After LAAO","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-07-06","conditions":"Atrial Fibrillation","enrollment":4220},{"nctId":"NCT05910125","phase":"PHASE4","title":"Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-07","conditions":"Ischemic Stroke","enrollment":472},{"nctId":"NCT03649711","phase":"PHASE3","title":"Chronic Kidney Disease (CKD) Platelet Study","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2018-11-01","conditions":"Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic","enrollment":76},{"nctId":"NCT02869009","phase":"PHASE3","title":"Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2016-11","conditions":"Ischemic Stroke","enrollment":3000},{"nctId":"NCT05573958","phase":"PHASE4","title":"To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Sarmad Zahoor","startDate":"2022-10-01","conditions":"Acute Coronary Syndrome","enrollment":90},{"nctId":"NCT03661411","phase":"PHASE4","title":"Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2018-10-17","conditions":"Stroke","enrollment":760},{"nctId":"NCT01121224","phase":"PHASE4","title":"Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-01-11","conditions":"Saphenous Vein Graft Atherosclerosis","enrollment":597},{"nctId":"NCT03198741","phase":"PHASE4","title":"Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation","status":"COMPLETED","sponsor":"Shenyang Northern Hospital","startDate":"2017-07-13","conditions":"Gastrointestinal Injury, Ischemic Heart Disease","enrollment":783},{"nctId":"NCT04078737","phase":"PHASE3","title":"Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2019-09-23","conditions":"Stroke, Transient Ischemic Attack","enrollment":6412},{"nctId":"NCT05125549","phase":"PHASE1","title":"Fasted Bioequivalence Study of Clopidogrel Film-coated Tablets, 75 mg in 48 Healthy, Adult Male and Female Subjects.","status":"COMPLETED","sponsor":"Joint Stock Company \"Farmak\"","startDate":"2018-07-12","conditions":"Pharmacokinetics","enrollment":48},{"nctId":"NCT02989558","phase":"PHASE3","title":"A Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events During TAVI","status":"COMPLETED","sponsor":"University of Athens","startDate":"2016-12","conditions":"Aortic Valve Stenosis","enrollment":90},{"nctId":"NCT04671069","phase":"PHASE1","title":"Drug Interaction Study of MGL-3196 With Clopidogrel","status":"COMPLETED","sponsor":"Madrigal Pharmaceuticals, Inc.","startDate":"2019-07-26","conditions":"Healthy","enrollment":20},{"nctId":"NCT03008083","phase":"PHASE4","title":"Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation","status":"UNKNOWN","sponsor":"Shanghai MicroPort Medical (Group) Co., Ltd.","startDate":"2019-01-10","conditions":"Drug-Eluting Stents, Percutaneous Coronary Intervention","enrollment":2446},{"nctId":"NCT02944123","phase":"PHASE3","title":"Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2016-09","conditions":"Acute Coronary Syndrome","enrollment":120},{"nctId":"NCT02506140","phase":"PHASE2, PHASE3","title":"Platelet Reactivity in Acute Non-disabling Cerebrovascular Events","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2015-08","conditions":"Stroke, Ischemic Attack, Transient","enrollment":675},{"nctId":"NCT00979589","phase":"PHASE3","title":"Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2009-12","conditions":"Stroke, Transient Ischemic Attack","enrollment":5100},{"nctId":"NCT04171687","phase":"PHASE1","title":"Effect of Tegoprazan or RAPA113 on Pharmacodynamics/Pharmacokinetics of Clopidogrel in Healthy Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2019-10-21","conditions":"Healthy","enrollment":36},{"nctId":"NCT02556203","phase":"PHASE3","title":"Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes","status":"TERMINATED","sponsor":"Bayer","startDate":"2015-12-16","conditions":"Transcatheter Aortic Valve Replacement","enrollment":1653},{"nctId":"NCT02260622","phase":"PHASE2","title":"Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2014-10","conditions":"Critical Limb Ischemia","enrollment":20},{"nctId":"NCT03814642","phase":"PHASE1","title":"Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2019-01-21","conditions":"Healthy","enrollment":25},{"nctId":"NCT04023630","phase":"PHASE4","title":"DUAL Antithrombotic Therapy in Patients With AF and ACS","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2019-10-01","conditions":"Atrial Fibrillation, Acute Coronary Syndromes","enrollment":4000},{"nctId":"NCT01768637","phase":"PHASE1","title":"Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-01","conditions":"Chronic Kidney Disease","enrollment":48},{"nctId":"NCT02748330","phase":"PHASE4","title":"Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2016-06","conditions":"Coronary Artery Disease, Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT01802775","phase":"PHASE2","title":"Edoxaban in Peripheral Arterial Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2013-02-06","conditions":"Peripheral Arterial Disease","enrollment":203},{"nctId":"NCT02298088","phase":"PHASE3","title":"Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis","status":"COMPLETED","sponsor":"Hospital do Coracao","startDate":"2015-08","conditions":"Acute ST Segment Elevation Myocardial Infarction, Thrombolysis in Myocardial Infarction Flow","enrollment":3799},{"nctId":"NCT02560688","phase":"PHASE1","title":"Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-12","conditions":"Drug Interaction","enrollment":22},{"nctId":"NCT02094963","phase":"PHASE4","title":"Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management","status":"COMPLETED","sponsor":"Seung-Jung Park","startDate":"2014-07-05","conditions":"Acute Coronary Syndrome, Myocardial Ischemia, Heart Diseases","enrollment":800},{"nctId":"NCT02164864","phase":"PHASE3","title":"Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-07-22","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2725},{"nctId":"NCT01896557","phase":"PHASE4","title":"Ranitidin Versus Omeprazole in Patients Taking Clopidogrel","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2011-10","conditions":"Coronary Artery Disease, Drug Interaction Potentiation","enrollment":92},{"nctId":"NCT03150667","phase":"PHASE4","title":"Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD","status":"UNKNOWN","sponsor":"North Texas Veterans Healthcare System","startDate":"2017-04-10","conditions":"Chronic Kidney Diseases, Acute Coronary Syndrome","enrollment":220},{"nctId":"NCT02048085","phase":"PHASE4","title":"Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis","status":"WITHDRAWN","sponsor":"Medical Center of South Arkansas","startDate":"2014-01-02","conditions":"Acute ST Segment Elevation Myocardial Infarction, Acute Coronary Syndrome","enrollment":""},{"nctId":"NCT02140801","phase":"PHASE4","title":"Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2014-05-01","conditions":"Thrombosis","enrollment":352},{"nctId":"NCT01860105","phase":"PHASE1","title":"Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Evaluation","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2012-09","conditions":"Pharmacokinetics and Pharmacodynamics in Healthy Volunteers","enrollment":37},{"nctId":"NCT01830543","phase":"PHASE3","title":"A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-05-10","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2124},{"nctId":"NCT03159559","phase":"PHASE4","title":"PGE1 Improves Coronary Microcirculation Dysfunction in Patients With CAD and Diabetes","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2017-01","conditions":"Coronary Microvascular Perfusion in Patients With Ischemic Heart Disease","enrollment":60},{"nctId":"NCT02185534","phase":"PHASE1","title":"Clopidogrel Bioequivalence Study in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-08","conditions":"Bioequivalence, AUC, Cmax, Pharmacokinetics","enrollment":144},{"nctId":"NCT02052635","phase":"PHASE4","title":"Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2014-09","conditions":"Non-ST Elevation Acute Coronary Syndrome","enrollment":34},{"nctId":"NCT01586975","phase":"PHASE2, PHASE3","title":"Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-07","conditions":"Stroke, Myocardial Infarctions","enrollment":93},{"nctId":"NCT01603082","phase":"PHASE4","title":"Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Acute Coronary Syndrome","enrollment":343},{"nctId":"NCT02609698","phase":"PHASE4","title":"ISAR-DAPT (A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial)","status":"UNKNOWN","sponsor":"Ajou University School of Medicine","startDate":"2015-08","conditions":"Stable Angina, Unstable Angina, Silent Coronary Ischemia, Coronary Artery Disease","enrollment":906},{"nctId":"NCT02446730","phase":"PHASE4","title":"Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Chonnam National University Hospital","startDate":"2014-09","conditions":"Cardiac Death, Hemorrhage, Cerebrovascular Accident","enrollment":1400},{"nctId":"NCT01864005","phase":"PHASE4","title":"A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-05","conditions":"Non-ST or ST Elevation Acute Coronary Syndromes","enrollment":60},{"nctId":"NCT01706510","phase":"PHASE4","title":"Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients","status":"COMPLETED","sponsor":"Rapid City Regional Hospital, Inc","startDate":"2012-12","conditions":"Coronary Artery Disease","enrollment":28},{"nctId":"NCT01174693","phase":"PHASE4","title":"Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2010-03","conditions":"Cerebral Infarction","enrollment":795},{"nctId":"NCT01763749","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin","status":"COMPLETED","sponsor":"Seoul St. Mary's Hospital","startDate":"2012-10","conditions":"Coronary Artery Disease","enrollment":91},{"nctId":"NCT02121288","phase":"PHASE4","title":"Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Peripheral Artery Disease, Vascular Disease, Arterial Occlusion Disease","enrollment":""},{"nctId":"NCT01523392","phase":"PHASE4","title":"A Pharmacodynamic Study With Ticagrelor in African American Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-03","conditions":"Stable Coronary Artery Disease","enrollment":50},{"nctId":"NCT01523366","phase":"PHASE4","title":"A Pharmacodynamic Study With Ticagrelor in Hispanic Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-04","conditions":"Stable Coronary Artery Disease","enrollment":53},{"nctId":"NCT02201667","phase":"PHASE4","title":"Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2014-08","conditions":"Acute Coronary Syndrome","enrollment":444},{"nctId":"NCT02171598","phase":"PHASE1","title":"Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Healthy","enrollment":44},{"nctId":"NCT01744288","phase":"PHASE1","title":"Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-12","conditions":"Inhibition on Platelet Aggregation","enrollment":258},{"nctId":"NCT01388660","phase":"PHASE1","title":"Pharmacokinetic Assessment of Simultaneous Administration of Clopidogrel and Aspirin","status":"UNKNOWN","sponsor":"Ajou University School of Medicine","startDate":"2011-06","conditions":"Coronary Artery Disease","enrollment":60},{"nctId":"NCT01482117","phase":"NA","title":"The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers","status":"COMPLETED","sponsor":"Inje University","startDate":"2011-11","conditions":"Interaction","enrollment":28},{"nctId":"NCT01757262","phase":"PHASE3","title":"A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2013-01","conditions":"Coronary Heart Disease","enrollment":""},{"nctId":"NCT01409616","phase":"PHASE1","title":"To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04","conditions":"Pharmacodynamic Interaction, Healthy Subjects","enrollment":100},{"nctId":"NCT01657071","phase":"PHASE1","title":"Comparative Pharmacokinetics of YH14659 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2012-03","conditions":"Acute Coronary Syndrome","enrollment":60},{"nctId":"NCT01621763","phase":"PHASE1","title":"Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2008-09","conditions":"Healthy","enrollment":68},{"nctId":"NCT01621750","phase":"PHASE1","title":"Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2008-08","conditions":"Fasting","enrollment":68},{"nctId":"NCT01557335","phase":"PHASE1","title":"A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540","status":"COMPLETED","sponsor":"POZEN","startDate":"2010-11","conditions":"Platelet Aggregation","enrollment":30},{"nctId":"NCT00942175","phase":"PHASE1","title":"A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-12","conditions":"Healthy","enrollment":160},{"nctId":"NCT01512485","phase":"PHASE1","title":"Bioequivalence Study of Clopidogrel Tablets 75 mg Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2006-10","conditions":"Healthy","enrollment":51},{"nctId":"NCT01506713","phase":"PHASE1","title":"Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2006-09","conditions":"Fasting","enrollment":53},{"nctId":"NCT01448330","phase":"PHASE1","title":"A Bioequivalence Study Comparing Clopidogrel/Aspirin Combination Tablet With Coadministration of Clopidogrel and Aspirin","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2011-07","conditions":"Healthy","enrollment":64},{"nctId":"NCT01210339","phase":"PHASE1","title":"An Interaction Study to Evaluate the Effect of Esomeprazole/Acetylsalicylic Acid on the Metabolism and Effect of Clopidogrel","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Healthy Volunteers","enrollment":58},{"nctId":"NCT01447563","phase":"PHASE1","title":"Comparative Bioavailability Study of Two Oral Formulations of Clopidogrel","status":"TERMINATED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2008-05","conditions":"Comparative Bioavailability of Clopidogrel Tablets","enrollment":32},{"nctId":"NCT01147588","phase":"PHASE1","title":"Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-05","conditions":"Healthy","enrollment":149},{"nctId":"NCT00356135","phase":"PHASE2","title":"Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-07","conditions":"Coronary Arteriosclerosis, Acute Coronary Syndrome","enrollment":139},{"nctId":"NCT00385944","phase":"PHASE2","title":"The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-03","conditions":"Acute Coronary Syndrome","enrollment":56},{"nctId":"NCT01129063","phase":"PHASE1","title":"Pharmacokinetic Study of Single Doses of Clopidogrel, 75 mg and 300 mg, in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-03","conditions":"Healthy","enrollment":32},{"nctId":"NCT01103843","phase":"NA","title":"Plavix, Prasugrel and Drug Eluting Stents Pilot Trial","status":"UNKNOWN","sponsor":"St. Francis Hospital, New York","startDate":"2010-04","conditions":"Coronary Artery Disease, Platelet Aggregation Inhibitors, PCI- Percutaneous Coronary Intervention","enrollment":1000},{"nctId":"NCT00853450","phase":"PHASE1","title":"Bleeding Time Study With AZD6482, Clopidogrel and ASA","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Antiplatelet Effect","enrollment":28},{"nctId":"NCT00620802","phase":"PHASE1","title":"Pharmacodynamics of CGT 2168 Compared With Plavix®","status":"COMPLETED","sponsor":"Cogentus Pharmaceuticals","startDate":"2007-11","conditions":"Healthy","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":259,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Thienopyridine (open-label)","genericName":"Thienopyridine (open-label)","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darexaban is a small molecule with an unknown mechanism of action, as per ChEMBL. It has been studied in clinical trials for its interaction with Acetyl Salicylic Acid (Aspirin) and Clopidogrel in conditions such as ischemic stroke, drug-eluting stents, and percutaneous coronary intervention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}